Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Delcath Systems, Inc. (DCTH)
USD12.81
-0.06 (-0.47%)
US NASDAQ Healthcare Medical - Devices
Address
1633 Broadway 10019
New York City, NY, US
New York City, NY, US
CEO
Gerard J. Michel
Website
delcath.com
IPO
2018-05-03
CIK 872912 ISIN US24661P8077
Description
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.81
-0.06 (-0.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
475.4K
Beta
0.49
Float Shares
28.78M
Free Float %
82.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.53% | -1.48% | +12.95% | +24.34% | +32.01% | +12.28% | -21.52% | +88.69% | +18.87% | -98.80% | -98.80% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
12.81
Low
19.00
+48.3%
Consensus
23.00
+79.5%
Median
23.00
+79.5%
High
27.00
+110.8%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
23.00
+79.5%
|
| Last Year | 4 |
24.00
+87.4%
|
| All Time | 6 |
23.67
+84.8%
|
Quality scores
Altman Z-Score
14.85
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
2 / 5
Medium
ROA Score
3 / 5
Medium
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+129.1% ★ Q1'26: +26.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+107.3% ★ Q1'26: -209.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-0.4% Q1'26: +1.1% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+4.1% Q1'26: -6.5% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+12.8% ★ Q1'26: -26.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+40.0% Q1'26: -8.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.24× ★ Q1'26: -0.15× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 6 Rev. Ana. 4 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.75M
est: 1.31M (+33.5%)
|
1.99M
est: 2.06M (-3.3%)
|
2.72M
est: 11.30M (-76.0%)
|
3.41M
est: 17.40M (-80.4%)
|
1.65M
est: 1.57M (+4.9%)
|
3.56M
est: 1.94M (+83.5%)
|
2.72M
est: 2.91M (-6.7%)
|
2.07M
est: 4.61M (-55.2%)
|
37.21M
est: 35.72M (+4.2%)
|
85.23M
est: 85.08M (+0.2%)
|
103.87M
100.87M – 108.06M
+22.1% YoY
|
134.28M
130.41M – 139.70M
+29.3% YoY
|
158.27M
155.18M – 161.37M
+17.9% YoY
|
182.45M
177.19M – 189.81M
+15.3% YoY
|
212.34M
206.22M – 220.91M
+16.4% YoY
|
| EBITDA |
-14.09M
est: -1.13M (-1,143.4%)
|
-3.34M
est: -1.78M (-87.1%)
|
-23.10M
est: -9.78M (-136.2%)
|
-10.82M
est: -15.06M (+28.2%)
|
-23.81M
est: -1.36M (-1,653.7%)
|
-24.32M
est: -1.68M (-1,350.1%)
|
-33.69M
est: -2.52M (-1,236.1%)
|
-37.78M
est: -3.02M (-1,149.4%)
|
-12.18M
est: -23.45M (+48.0%)
|
3.86M
est: -55.85M (+106.9%)
|
-68.18M
-70.93M – -66.21M
-22.1% YoY
|
-88.14M
-91.70M – -85.60M
-29.3% YoY
|
-103.90M
-105.93M – -101.86M
-17.9% YoY
|
-119.76M
-124.60M – -116.31M
-15.3% YoY
|
-139.39M
-145.01M – -135.37M
-16.4% YoY
|
| EBIT |
-14.70M
est: -1.13M (-1,196.0%)
|
-3.64M
est: -1.79M (-103.9%)
|
-23.41M
est: -9.79M (-139.1%)
|
-11.26M
est: -15.08M (+25.3%)
|
-23.98M
est: -1.36M (-1,663.5%)
|
-24.46M
est: -1.68M (-1,356.7%)
|
-33.82M
est: -2.53M (-1,239.5%)
|
-38.18M
est: -3.03M (-1,158.6%)
|
-12.41M
est: -23.52M (+47.2%)
|
3.51M
est: -56.02M (+106.3%)
|
-68.39M
-71.15M – -66.42M
-22.1% YoY
|
-88.42M
-91.99M – -85.87M
-29.3% YoY
|
-104.22M
-106.26M – -102.18M
-17.9% YoY
|
-120.14M
-124.98M – -116.67M
-15.3% YoY
|
-139.82M
-145.47M – -135.79M
-16.4% YoY
|
| Net Income |
-14.70M
est: -32,970.58T (+100.0%)
|
-17.97M
est: -62,588.21T (+100.0%)
|
-45.12M
est: -107,294.08T (+100.0%)
|
-19.22M
est: -94,441.14T (+100.0%)
|
-24.16M
est: -215.19M (+88.8%)
|
-25.65M
est: -110.68M (+76.8%)
|
-36.51M
est: -107.56M (+66.1%)
|
-47.68M
est: -103.61M (+54.0%)
|
-26.39M
est: -30.88M (+14.6%)
|
2.70M
est: 2.00M (+35.1%)
|
-22.41M
-23.41M – -21.41M
-1,221.0% YoY
|
-15.34M
-16.03M – -14.66M
+31.5% YoY
|
-1.26M
-4.67M – 2.15M
+91.8% YoY
|
9.65M
9.29M – 10.15M
+865.9% YoY
|
27.62M
26.59M – 29.07M
+186.3% YoY
|
| SGA |
10.01M
est: 7.45M (+34.4%)
|
9.43M
est: 11.73M (-19.6%)
|
9.68M
est: 64.30M (-84.9%)
|
9.82M
est: 99.00M (-90.1%)
|
11.11M
est: 8.93M (+24.4%)
|
13.64M
est: 11.02M (+23.7%)
|
17.30M
est: 16.58M (+4.4%)
|
22.11M
est: 20.47M (+8.0%)
|
29.55M
est: 158.67M (-81.4%)
|
43.53M
est: 377.93M (-88.5%)
|
461.41M
448.10M – 480.03M
+22.1% YoY
|
596.51M
579.31M – 620.59M
+29.3% YoY
|
703.11M
689.37M – 716.85M
+17.9% YoY
|
810.49M
787.12M – 843.20M
+15.3% YoY
|
943.31M
916.11M – 981.38M
+16.4% YoY
|
| EPS |
-1,783,941,176.00
est: -1,156,400,000.00 (-54.3%)
|
-1,298,361,519.00
est: -2,195,200,000.00 (+40.9%)
|
-2,272,727.00
est: -3,763,200,000.00 (+99.9%)
|
-503.85
est: -3,312,399,872.00 (+100.0%)
|
-8.35
est: -7.55 (-10.7%)
|
-3.59
est: -3.88 (+7.5%)
|
-4.12
est: -3.77 (-9.2%)
|
-2.94
est: -2.55 (-15.3%)
|
-0.93
est: -0.77 (-19.6%)
|
0.08
est: 0.05 (+51.7%)
|
-0.56
-0.59 – -0.54
-1,221.0% YoY
|
-0.38
-0.40 – -0.37
+31.5% YoY
|
-0.03
-0.12 – 0.05
+92.1% YoY
|
0.24
0.23 – 0.25
+905.6% YoY
|
0.69
0.67 – 0.73
+186.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
20.57M
OE per share TTM
0.53
Owner's Yield
5.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
7.61M
Insider transactions (90d)
0
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF Inc. | 1.56M | 9.99% | — | — | — | 1.56M | CO | Delaware | 2023-06-22 | ↗ |
| 2 | BVF Partners L.P. | 1.56M | 9.99% | — | — | — | 1.56M | IA, PN | Delaware | 2023-06-22 | ↗ |
| 3 | Mark N. Lampert | 1.56M | 9.99% | — | — | — | 1.56M | IN | Delaware | 2023-06-22 | ↗ |
| 4 | 27-4413262 | 1.54M | 6.80% | 1.54M | — | 1.54M | — | OO | Maryland | 2024-01-09 | ↗ |
| 5 | Identification Nos. of above persons (. | 1.54M | 6.80% | 1.54M | — | 1.54M | — | IN | Maryland | 2024-01-09 | ↗ |
| 6 | BVF GP Holdings LLC | 1.49M | 9.60% | — | — | — | 1.49M | OO | Delaware | 2023-06-22 | ↗ |
| 7 | BVF I GP LLC | 1.01M | 6.50% | — | — | — | 1.01M | OO | Delaware | 2023-06-22 | ↗ |
| 8 | Biotechnology Value Fund, L.P. | 1.01M | 6.50% | — | — | — | 1.01M | PN | Delaware | 2023-06-22 | ↗ |
| 9 | Group, LLC | 806.4K | 5.30% | — | 806.4K | — | 806.4K | OO | Cayman Islands | 2023-08-16 | ↗ |
| 10 | LLC | 806.4K | 5.30% | — | 806.4K | — | 806.4K | OO | Cayman Islands | 2023-08-16 | ↗ |
| 11 | Levy | 806.4K | 5.30% | — | 806.4K | — | 806.4K | IN | Cayman Islands | 2023-08-16 | ↗ |
| 12 | Master Fund, L.P. | 806.4K | 5.30% | — | 806.4K | — | 806.4K | FI | Cayman Islands | 2023-08-16 | ↗ |
| 13 | Company, L.P. | 500.0K | 8.75% | — | 500.0K | — | — | PN | Delaware | 2020-12-17 | ↗ |
| 14 | Deerfield Mgmt, L.P. | 500.0K | 8.75% | — | 500.0K | — | — | PN | Delaware | 2020-12-17 | ↗ |
| 15 | Deerfield Partners, L.P. | 500.0K | 8.75% | — | 500.0K | — | — | PN | Delaware | 2020-12-17 | ↗ |
| 16 | James E. Flynn | 500.0K | 8.75% | — | 500.0K | — | — | IN | Delaware | 2020-12-17 | ↗ |
| 17 | BVF II GP LLC | 482.4K | 3.20% | — | — | — | 482.4K | OO | Delaware | 2023-06-22 | ↗ |
| 18 | Biotechnology Value Fund II, L.P. | 482.4K | 3.20% | — | — | — | 482.4K | PN | Delaware | 2023-06-22 | ↗ |
| 19 | S | 304.5K | 9.90% | — | 304.5K | — | 304.5K | PN | ONTARIO, CANADA | 2020-03-06 | ↗ |
| 20 | Hudson Bay Capital Management LP | 156.9K | 2.67% | — | 156.9K | — | — | PN | State of Delaware | 2021-02-09 | ↗ |
| 21 | Sander Gerber | 156.9K | 2.67% | — | 156.9K | — | — | IN | United States | 2021-02-09 | ↗ |
| 22 | Growth GP, LLC | 134.1K | 9.90% | — | 134.1K | — | — | PN | — | 2020-02-14 | ↗ |
| 23 | Altium Capital Management, LP | 99.8K | 4.99% | — | 99.8K | — | — | IA, PN | Delaware, United States of America | 2021-02-16 | ↗ |
| 24 | Altium Growth Fund, LP | 99.8K | 4.99% | — | 99.8K | — | — | PN | Delaware, United States of America | 2021-02-16 | ↗ |
| 25 | Altium Growth GP, LLC | 99.8K | 4.99% | — | 99.8K | — | — | OO | Delaware, United States of America | 2021-02-16 | ↗ |
| 26 | Norbert Gottesman | 52.1K | 6.29% | 52.1K | — | 52.1K | — | IN | Delaware | 2020-09-24 | ↗ |
| 27 | Triple Gate Capital GP, LLC. 47-5029655 | 52.1K | 6.29% | 52.1K | — | 52.1K | — | OO | Delaware | 2020-09-24 | ↗ |
| 28 | Triple Gate Capital, LP. 32-0474905 | 52.1K | 6.29% | 52.1K | — | 52.1K | — | PN | Delaware | 2020-09-24 | ↗ |
| 29 | Triple Gate Partners, LP. 36-4818051 | 52.1K | 6.29% | 52.1K | — | 52.1K | — | PN | Delaware | 2020-09-24 | ↗ |
| 30 | BVF Partners OS Ltd. | 51.5K | 1.00% | — | — | — | 51.5K | CO | Delaware | 2023-06-22 | ↗ |
| 31 | Biotechnology Value Trading Fund OS LP | 51.5K | 1.00% | — | — | — | 51.5K | PN | Delaware | 2023-06-22 | ↗ |
| 32 | Guoqing Ma | 5.8K | 0.09% | 5.8K | — | 5.8K | — | IN | China | 2021-04-09 | ↗ |
| 33 | Devesh Gandhi | — | 0.00% | — | — | — | — | IN | United States | 2022-02-08 | ↗ |
| 34 | SilverArc Capital Management, LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-97 vs prev Q
New positions
7
Closed positions
99
Increased
12
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ROSALIND ADVISORS, INC. | 3.30M +— (+0.0%) | 33.00M +— (+0.0%) | 9.07% -0.151 pp | 11.60% +0.319 pp | USD7.96 +26.9% | 9 qtrs — |
| 2 | BLACKROCK, INC. | 1.83M +56.1K (+3.2%) | 18.43M -582.9K (-3.1%) | 5.02% +0.073 pp | 0.00% +0.000 pp | USD13.11 -23.0% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 1.67M +14.9K (+0.9%) | 16.89M -926.5K (-5.2%) | 4.60% -0.035 pp | 0.00% +0.000 pp | USD10.46 -3.4% | 21 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 682.8K -4.8K (-0.7%) | 6.90M -495.4K (-6.7%) | 1.88% -0.045 pp | 0.00% +0.000 pp | USD11.37 -11.2% | 21 qtrs — |
| 5 | STATE STREET CORP | 608.0K -13.2K (-2.1%) | 6.14M -537.6K (-8.0%) | 1.67% -0.065 pp | 0.00% +0.000 pp | USD11.90 -15.1% | 18 qtrs — |
| 6 | GOLDMAN SACHS GROUP INC | 587.7K +315.6K (+116.0%) | 5.94M +3.0M (+102.9%) | 1.62% +0.855 pp | 0.00% +0.000 pp | USD10.74 -6.0% | 7 qtrs — |
| 7 | DIVISADERO STREET CAPITAL MANAGEMENT, LP | 499.8K +23.6K (+5.0%) | 5.05M -70.8K (-1.4%) | 1.37% +0.043 pp | 0.24% +0.013 pp | USD10.72 -5.8% | 2 qtrs — |
| 8 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 496.7K +117.1K (+30.9%) | 5.02M +936.2K (+22.9%) | 1.37% +0.305 pp | 0.04% -0.002 pp | USD10.60 -4.7% | 6 qtrs — |
| 9 | PROPEL BIO MANAGEMENT, LLC | 438.5K +— (+0.0%) | 4.43M -285.0K (-6.0%) | 1.21% -0.020 pp | 3.78% -0.938 pp | USD11.84 -14.7% | 5 qtrs — |
| 10 | IKARIAN CAPITAL, LLC | 431.3K +— (+0.0%) | 4.36M -280.3K (-6.0%) | 1.19% -0.020 pp | 0.34% -0.128 pp | USD11.64 -13.2% | 7 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 361.6K +105.4K (+41.1%) | 3.65M +898.0K (+32.6%) | 0.99% +0.278 pp | 0.01% +0.002 pp | USD11.02 -8.3% | 7 qtrs — |
| 12 | MORGAN STANLEY | 308.6K +55.5K (+21.9%) | 3.12M +396.4K (+14.6%) | 0.85% +0.141 pp | 0.00% +0.000 pp | USD11.37 -11.2% | 22 qtrs — |
| 13 | PRIVATE WEALTH ADVISORS, LLC | 290.5K +134.2K (+85.9%) | 2.93M +1.3M (+74.6%) | 0.80% +0.362 pp | 0.94% +0.372 pp | USD11.75 -14.0% | 4 qtrs — |
| 14 | PALISADES INVESTMENT PARTNERS, LLC | 267.1K +4.2K (+1.6%) | 2.70M -128.7K (-4.6%) | 0.73% -0.001 pp | 1.02% -0.091 pp | USD10.94 -7.7% | 6 qtrs — |
| 15 | SIMPLIFY ASSET MANAGEMENT INC. | 261.1K +— (+0.0%) | 2.64M -169.7K (-6.0%) | 0.72% -0.012 pp | 0.04% -0.009 pp | USD11.52 -12.3% | 5 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 246.4K +7.2K (+3.0%) | 2.49M -82.9K (-3.2%) | 0.68% +0.009 pp | 0.00% 0.000 pp | USD10.41 -3.0% | 10 qtrs — |
| 17 | NORTHERN TRUST CORP | 240.6K -12.1K (-4.8%) | 2.43M -286.7K (-10.6%) | 0.66% -0.045 pp | 0.00% +0.000 pp | USD11.64 -13.2% | 19 qtrs — |
| 18 | ADAR1 CAPITAL MANAGEMENT, LLC | 224.4K +— (+0.0%) | 2.27M -145.9K (-6.0%) | 0.62% -0.010 pp | 0.17% -0.060 pp | USD10.52 -4.0% | 9 qtrs — |
| 19 | DIAMETRIC CAPITAL, LP | 220.2K +134.0K (+155.4%) | 2.22M +1.3M (+139.9%) | 0.61% +0.364 pp | 0.60% +0.252 pp | USD10.35 -2.4% | 6 qtrs — |
| 20 | KENNEDY CAPITAL MANAGEMENT LLC | 202.8K -211.1K (-51.0%) | 2.05M -2.4M (-54.0%) | 0.56% -0.599 pp | 0.04% -0.055 pp | USD10.91 -7.4% | 6 qtrs — |
| 21 | UBS GROUP AG | 199.0K +84.2K (+73.3%) | 2.01M +775.4K (+62.8%) | 0.55% +0.226 pp | 0.00% +0.000 pp | USD11.04 -8.5% | 13 qtrs — |
| 22 | LANE GENERATIONAL LLC | 197.7K +197.7K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.54% +0.543 pp | 1.81% +1.809 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 23 | ALGERT GLOBAL LLC | 171.6K +171.6K (+100.0%) | 1.73M +1.7M (+100.0%) | 0.47% +0.472 pp | 0.03% +0.027 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 24 | CIBC WORLD MARKET INC. | 158.9K -19.6K (-11.0%) | 1.60M -314.0K (-16.4%) | 0.44% -0.062 pp | 0.00% -0.001 pp | USD6.46 +56.3% | 17 qtrs — |
| 25 | ROYCE & ASSOCIATES LP | 155.0K +155.0K (+100.0%) | 1.57M +1.6M (+100.0%) | 0.43% +0.426 pp | 0.02% +0.016 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 26 | APIS CAPITAL ADVISORS, LLC | 136.0K -110.0K (-44.7%) | 1.37M -1.3M (-48.1%) | 0.37% -0.314 pp | 0.24% -0.345 pp | USD12.10 -16.5% | 5 qtrs — |
| 27 | TREXQUANT INVESTMENT LP | 118.1K -697.0 (-0.6%) | 1.19M -84.2K (-6.6%) | 0.32% -0.007 pp | 0.01% -0.003 pp | USD13.21 -23.5% | 3 qtrs — |
| 28 | NEW YORK STATE COMMON RETIREMENT FUND | 114.6K -4.7K (-3.9%) | 1.16M -125.0K (-9.7%) | 0.31% -0.018 pp | 0.00% 0.000 pp | USD11.11 -9.1% | 6 qtrs — |
| 29 | CITADEL ADVISORS LLC | 113.1K +33.8K (+42.6%) | 1.14M +289.8K (+34.0%) | 0.31% +0.089 pp | 0.00% +0.000 pp | USD10.12 -0.2% | 10 qtrs — |
| 30 | QUBE RESEARCH & TECHNOLOGIES LTD | 103.8K -175.3K (-62.8%) | 1.05M -2.0M (-65.1%) | 0.29% -0.495 pp | 0.00% -0.002 pp | USD10.92 -7.5% | 7 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 101.0K +31.6K (+45.5%) | 1.02M +273.7K (+36.7%) | 0.28% +0.084 pp | 0.00% +0.000 pp | USD12.41 -18.6% | 3 qtrs — |
| 32 | CAPITAL ADVISORS WEALTH MANAGEMENT, LLC | 90.5K +5.0K (+5.8%) | 914.1K -5.1K (-0.6%) | 0.25% +0.010 pp | 0.12% -0.007 pp | USD12.43 -18.7% | 4 qtrs — |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 85.9K +261.0 (+0.3%) | 867.4K -53.0K (-5.8%) | 0.24% -0.003 pp | 0.00% +0.000 pp | USD13.36 -24.4% | 5 qtrs — |
| 34 | BARCLAYS PLC | 78.5K +67.0K (+583.7%) | 792.7K +689.1K (+664.8%) | 0.22% +0.184 pp | 0.00% +0.000 pp | USD10.32 -2.1% | 6 qtrs — |
| 35 | SQUAREPOINT OPS LLC | 75.1K +13.0K (+20.9%) | 758.9K +90.9K (+13.6%) | 0.21% +0.033 pp | 0.00% +0.000 pp | USD10.56 -4.4% | 6 qtrs — |
| 36 | JANE STREET GROUP, LLC | 74.5K +14.4K (+24.0%) | 752.5K +106.4K (+16.5%) | 0.20% +0.037 pp | 0.00% +0.000 pp | USD10.62 -4.9% | 2 qtrs — |
| 37 | BOOTHBAY FUND MANAGEMENT, LLC | 73.0K -43.1K (-37.1%) | 737.1K -511.1K (-40.9%) | 0.20% -0.124 pp | 0.01% -0.007 pp | USD10.71 -5.7% | 7 qtrs — |
| 38 | XTX TOPCO LTD | 71.2K +55.0K (+339.4%) | 719.0K +544.9K (+312.8%) | 0.20% +0.150 pp | 0.02% +0.010 pp | USD10.90 -7.3% | 3 qtrs — |
| 39 | GSA CAPITAL PARTNERS LLP | 67.8K +67.8K (+100.0%) | 685.0K +685.0K (+100.0%) | 0.19% +0.186 pp | 0.06% +0.059 pp | USD10.10 +0.0% | 5 qtrs — |
| 40 | NUVEEN, LLC | 66.4K +— (+0.0%) | 670.2K -43.1K (-6.0%) | 0.18% -0.003 pp | 0.00% +0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 41 | NOMURA HOLDINGS INC | 64.4K +43.8K (+212.2%) | 650.1K +428.5K (+193.3%) | 0.18% +0.119 pp | 0.00% +0.001 pp | USD11.22 -10.0% | 5 qtrs — |
| 42 | LOS ANGELES CAPITAL MANAGEMENT LLC | 68.3K +829.0 (+1.2%) | 642.3K -83.3K (-11.5%) | 0.19% -0.001 pp | 0.00% 0.000 pp | USD13.56 -25.5% | 3 qtrs — |
| 43 | AWM INVESTMENT COMPANY, INC. | 60.0K +2.3K (+3.9%) | 606.0K -14.5K (-2.3%) | 0.16% +0.004 pp | 0.06% +0.000 pp | USD10.73 -5.9% | 2 qtrs — |
| 44 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 57.8K -7.3K (-11.3%) | 583.6K -116.5K (-16.6%) | 0.16% -0.023 pp | 0.00% +0.000 pp | USD11.76 -14.1% | 7 qtrs — |
| 45 | BALYASNY ASSET MANAGEMENT L.P. | 52.1K +21.4K (+69.5%) | 526.6K +196.0K (+59.3%) | 0.14% +0.057 pp | 0.00% +0.000 pp | USD10.48 -3.6% | 4 qtrs — |
| 46 | AMERIPRISE FINANCIAL INC | 47.1K +3.8K (+8.9%) | 475.5K +10.7K (+2.3%) | 0.13% +0.009 pp | 0.00% +0.000 pp | USD12.41 -18.6% | 3 qtrs — |
| 47 | JUMP FINANCIAL, LLC | 46.0K +18.6K (+68.0%) | 464.1K +170.0K (+57.8%) | 0.13% +0.050 pp | 0.01% +0.002 pp | USD11.75 -14.0% | 7 qtrs — |
| 48 | PRELUDE CAPITAL MANAGEMENT, LLC | 43.3K +10.0K (+30.0%) | 437.7K +79.3K (+22.1%) | 0.12% +0.026 pp | 0.03% +0.004 pp | USD10.14 -0.4% | 6 qtrs — |
| 49 | PALE FIRE CAPITAL SE | 40.1K +40.1K (+100.0%) | 404.9K +404.9K (+100.0%) | 0.11% +0.110 pp | 0.03% +0.027 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 50 | MAN GROUP PLC | 38.2K +9.7K (+34.1%) | 385.4K +79.5K (+26.0%) | 0.10% +0.025 pp | 0.00% +0.000 pp | USD12.29 -17.8% | 5 qtrs — |
| 51 | BANK OF AMERICA CORP /DE/ | 37.5K -73.2K (-66.1%) | 378.5K -810.8K (-68.2%) | 0.10% -0.206 pp | 0.00% 0.000 pp | USD12.58 -19.7% | 13 qtrs — |
| 52 | CREATIVE PLANNING | 37.3K +21.7K (+139.2%) | 376.4K +208.9K (+124.7%) | 0.10% +0.059 pp | 0.00% +0.000 pp | USD10.37 -2.6% | 2 qtrs — |
| 53 | TRIPLETAIL WEALTH MANAGEMENT, LLC | 36.8K +— (+0.0%) | 371.9K -39.4K (-9.6%) | 0.10% -0.002 pp | 0.47% -0.015 pp | USD13.60 -25.7% | 3 qtrs — |
| 54 | VERITION FUND MANAGEMENT LLC | 35.6K -238.0 (-0.7%) | 359.6K -25.7K (-6.7%) | 0.10% -0.002 pp | 0.00% 0.000 pp | USD11.46 -11.9% | 7 qtrs — |
| 55 | RHUMBLINE ADVISERS | 34.6K -7.9K (-18.7%) | 349.2K -107.7K (-23.6%) | 0.10% -0.024 pp | 0.00% 0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 56 | WELLS FARGO & COMPANY/MN | 32.8K +14.3K (+77.0%) | 331.5K +132.2K (+66.3%) | 0.09% +0.038 pp | 0.00% +0.000 pp | USD11.41 -11.5% | 16 qtrs — |
| 57 | — | 29.0K +29.0K (+100.0%) | 292.9K +292.9K (+100.0%) | 0.08% +0.080 pp | 0.01% +0.009 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 58 | ALPS ADVISORS INC | 29.0K +12.1K (+71.9%) | 292.9K +111.5K (+61.5%) | 0.08% +0.033 pp | 0.00% +0.001 pp | USD12.14 -16.8% | 3 qtrs — |
| 59 | AQUATIC CAPITAL MANAGEMENT LLC | 28.1K -3.8K (-11.9%) | 283.9K -59.2K (-17.2%) | 0.08% -0.012 pp | 0.01% +0.002 pp | USD12.28 -17.8% | 3 qtrs — |
| 60 | STONEPINE CAPITAL MANAGEMENT, LLC | 27.2K +27.2K (+100.0%) | 275.0K +275.0K (+100.0%) | 0.07% +0.075 pp | 0.20% +0.201 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 61 | QUANTBOT TECHNOLOGIES LP | 27.0K +27.0K (+100.0%) | 273.0K +273.0K (+100.0%) | 0.07% +0.074 pp | 0.01% +0.009 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 62 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 26.0K +24.0K (+1,194.5%) | 262.0K +241.0K (+1,147.6%) | 0.07% +0.066 pp | 0.00% +0.003 pp | USD10.15 -0.5% | 2 qtrs — |
| 63 | MARSHALL WACE, LLP | 24.3K -264.4K (-91.6%) | 245.9K -2.9M (-92.1%) | 0.07% -0.740 pp | 0.00% -0.003 pp | USD13.60 -25.7% | 3 qtrs — |
| 64 | DEUTSCHE BANK AG\ | 24.2K +1.2K (+5.4%) | 244.0K -2.3K (-0.9%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD13.07 -22.7% | 3 qtrs — |
| 65 | SEI INVESTMENTS CO | 22.0K +22.0K (+100.0%) | 222.5K +222.5K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.000 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 66 | CORSAIR CAPITAL MANAGEMENT, L.P. | 20.0K +20.0K (+100.0%) | 202.0K +202.0K (+100.0%) | 0.06% +0.055 pp | 0.03% +0.031 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 67 | METLIFE INVESTMENT MANAGEMENT, LLC | 18.7K +— (+0.0%) | 188.6K -12.1K (-6.0%) | 0.05% -0.001 pp | 0.00% 0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 68 | INTECH INVESTMENT MANAGEMENT LLC | 17.6K +2.0K (+13.1%) | 177.7K +10.4K (+6.2%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD13.02 -22.4% | 3 qtrs — |
| 69 | WEALTHPLAN INVESTMENT MANAGEMENT, LLC | 17.4K +— (+0.0%) | 176.2K -11.3K (-6.0%) | 0.05% -0.001 pp | 0.01% -0.001 pp | USD4.16 +142.8% | 9 qtrs — |
| 70 | INVESCO LTD. | 17.1K -2.0K (-10.4%) | 172.7K -32.4K (-15.8%) | 0.05% -0.006 pp | 0.00% +0.000 pp | USD12.73 -20.7% | 4 qtrs — |
| 71 | GROUP ONE TRADING, L.P. | 16.3K +14.4K (+765.2%) | 164.8K +144.5K (+712.9%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD10.18 -0.8% | 5 qtrs — |
| 72 | PRICE T ROWE ASSOCIATES INC /MD/ | 16.1K +— (+0.0%) | 163.0K -10.0K (-5.8%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD13.42 -24.7% | 3 qtrs — |
| 73 | ROYAL BANK OF CANADA | 16.0K +3.4K (+27.4%) | 162.0K +27.0K (+20.0%) | 0.04% +0.009 pp | 0.00% +0.000 pp | USD11.56 -12.6% | 11 qtrs — |
| 74 | SKYOAK WEALTH, LLC | 15.0K +15.0K (+100.0%) | 151.5K +151.5K (+100.0%) | 0.04% +0.041 pp | 0.03% +0.027 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 75 | ALLIANCEBERNSTEIN L.P. | 14.0K +— (+0.0%) | 141.4K -9.1K (-6.0%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 76 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 13.8K -334.0 (-2.4%) | 139.6K -12.6K (-8.3%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 77 | SIMPLEX TRADING, LLC | 13.3K -6.7K (-33.7%) | 134.2K -80.8K (-37.6%) | 0.04% -0.020 pp | 0.00% +0.000 pp | USD11.00 -8.2% | 14 qtrs — |
| 78 | JPMORGAN CHASE & CO | 12.9K +426.0 (+3.4%) | 130.6K -3.8K (-2.8%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD13.23 -23.7% | 4 qtrs — |
| 79 | HRT FINANCIAL LP | 12.6K -142.5K (-91.9%) | 127.0K -1.5M (-92.4%) | 0.03% -0.399 pp | 0.00% -0.006 pp | USD10.75 -6.0% | 4 qtrs — |
| 80 | HUNTING HILL GLOBAL CAPITAL, LLC | 12.3K -5.6K (-31.3%) | 124.1K -68.2K (-35.5%) | 0.03% -0.016 pp | 0.09% +0.032 pp | USD8.01 +26.1% | 10 qtrs — |
| 81 | SKOPOS LABS, INC. | 11.9K -30.2K (-71.8%) | 120.9K -331.8K (-73.3%) | 0.03% -0.085 pp | 0.01% -0.043 pp | USD10.75 -6.0% | 2 qtrs — |
| 82 | QUADRATURE CAPITAL LTD | 11.9K -2.1K (-15.2%) | 120.1K -30.7K (-20.4%) | 0.03% -0.007 pp | 0.00% -0.001 pp | USD13.60 -25.7% | 3 qtrs — |
| 83 | NBC SECURITIES, INC. | 11.7K -182.0 (-1.5%) | 118.0K -9.5K (-7.5%) | 0.03% -0.001 pp | 0.01% -0.001 pp | USD12.42 -18.7% | 7 qtrs — |
| 84 | PHARVISION ADVISERS, LLC | 11.2K -3.8K (-25.4%) | 113.3K -48.3K (-29.9%) | 0.03% -0.011 pp | 0.06% -0.034 pp | USD10.75 -6.0% | 2 qtrs — |
| 85 | SHERBROOKE PARK ADVISERS LLC | 10.9K +10.9K (+100.0%) | 109.9K +109.9K (+100.0%) | 0.03% +0.030 pp | 0.28% +0.284 pp | USD10.10 +0.0% | 1 qtrs NEW |
| 86 | SOLEUS CAPITAL MANAGEMENT, L.P. | 10.0K +— (+0.0%) | 101.0K -6.5K (-6.0%) | 0.03% -0.001 pp | 0.00% -0.002 pp | USD12.04 -16.1% | 5 qtrs — |
| 87 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 8.8K +— (+0.0%) | 88.8K -5.7K (-6.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD13.05 -22.6% | 3 qtrs — |
| 88 | FMR LLC | 7.5K +7.2K (+2,755.7%) | 75.6K +72.8K (+2,582.6%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD10.22 -1.2% | 3 qtrs — |
| 89 | BNP PARIBAS ARBITRAGE, SNC | 6.4K +611.0 (+10.5%) | 65.0K +2.4K (+3.8%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD13.27 -23.9% | 3 qtrs — |
| 90 | LEGAL & GENERAL GROUP PLC | 3.2K -189.0 (-5.6%) | 32.0K -4.1K (-11.3%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 91 | AMERITAS INVESTMENT PARTNERS, INC. | 3.1K +— (+0.0%) | 31.1K -2.0K (-6.0%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 92 | RUSSELL INVESTMENTS GROUP, LTD. | 2.7K +4.0 (+0.1%) | 27.4K -1.7K (-5.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD10.75 -6.0% | 2 qtrs — |
| 93 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 1.8K -49.0 (-2.6%) | 18.5K -1.7K (-8.5%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD13.60 -25.7% | 3 qtrs — |
| 94 | CITIGROUP INC | 1.5K +213.0 (+16.4%) | 15.2K +1.3K (+9.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD13.11 -23.0% | 6 qtrs — |
| 95 | QUEST PARTNERS LLC | 1.4K +1.4K (+100.0%) | 14.5K +14.5K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.001 pp | USD10.10 +0.0% | 4 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
14
Sells
0
Shares acquired
733.0K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+732,983
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | Pennell Sandra | Officer | P-Purchase | A | Common Stock | 5,533 | 9.04 | 50.0K | 77,018 | D | ↗ |
| 2026-03-02 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 11,200 | 8.96 | 100.3K | 342,034 | D | ↗ |
| 2026-02-17 | Vukovic Vojo | Officer | A-Award | A | Stock Option (Right to Buy) | 56,500 | 9.40 | 531.1K | 56,500 | D | ↗ |
| 2026-02-17 | Rook Martha S. | Officer | A-Award | A | Restricted Stock Units | 28,250 | 0.00 | — | 28,250 | D | ↗ |
| 2026-02-17 | Pennell Sandra | Officer | A-Award | A | Restricted Stock Units | 28,250 | 0.00 | — | 28,250 | D | ↗ |
| 2026-02-17 | Muir Kevin | Officer | A-Award | A | Restricted Stock Units | 28,250 | 0.00 | — | 28,250 | D | ↗ |
| 2026-02-17 | MICHEL GERARD J | Director / Officer | A-Award | A | Restricted Stock Units | 97,500 | 0.00 | — | 97,500 | D | ↗ |
| 2026-02-17 | Hoffman David L. | Officer | A-Award | A | Restricted Stock Units | 28,250 | 0.00 | — | 28,250 | D | ↗ |
| 2025-11-21 | Sylvester John Richard | Director | P-Purchase | A | Common Stock | 4,386 | 8.89 | 39.0K | 14,936 | D | ↗ |
| 2025-11-11 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 11,500 | 8.53 | 98.0K | 330,834 | D | ↗ |
| 2025-06-12 | Vukovic Vojo | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 42,000 | 4.78 | 200.8K | 58,500 | D | ↗ |
| 2025-05-15 | Sylvester John Richard | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 16.05 | 361.1K | 22,500 | D | ↗ |
| 2025-05-15 | SALAMON STEVEN A J | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 16.05 | 361.1K | 22,500 | D | ↗ |
| 2025-05-15 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 16.05 | 361.1K | 22,500 | D | ↗ |
| 2025-05-15 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 16.05 | 361.1K | 22,500 | D | ↗ |
| 2025-05-15 | Aharon Gil | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 16.05 | 361.1K | 22,500 | D | ↗ |
| 2025-05-05 | SALAMON STEVEN A J | Director | X-InTheMoney | A | Common shares | 400,000 | 10.00 | 4.00M | 3,413,468 | I | ↗ |
| 2025-05-05 | Rosalind Advisors, Inc. | Director | X-InTheMoney | A | Common shares | 400,000 | 10.00 | 4.00M | 3,413,468 | I | ↗ |
| 2025-05-05 | Aharon Gil | Director | X-InTheMoney | A | Common shares | 400,000 | 10.00 | 4.00M | 3,413,468 | I | ↗ |
| 2025-02-07 | Vukovic Vojo | Officer | A-Award | A | Stock Option (Right to Buy) | 113,000 | 16.25 | 1.84M | 113,000 | D | ↗ |
| 2025-02-07 | Rook Martha S. | Officer | A-Award | A | Stock Option (Right to Buy) | 113,000 | 16.25 | 1.84M | 113,000 | D | ↗ |
| 2025-02-07 | Pennell Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 113,000 | 16.25 | 1.84M | 113,000 | D | ↗ |
| 2025-02-07 | Muir Kevin | Officer | A-Award | A | Stock Option (Right to Buy) | 113,000 | 16.25 | 1.84M | 113,000 | D | ↗ |
| 2025-02-07 | MICHEL GERARD J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 390,000 | 16.25 | 6.34M | 390,000 | D | ↗ |
| 2025-02-07 | Hoffman David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 113,000 | 16.25 | 1.84M | 113,000 | D | ↗ |
| 2024-12-24 | SALAMON STEVEN A J | Director | C-Conversion | A | Common shares | 250,000 | 10.00 | 2.50M | 3,013,468 | I | ↗ |
| 2024-12-24 | Rosalind Advisors, Inc. | Director | M-Exempt | A | Pre-funded Warrants | 603,954 | 0.01 | 6.0K | 1,323,919 | I | ↗ |
| 2024-12-24 | Aharon Gil | Director | M-Exempt | A | Pre-funded Warrants | 603,954 | 0.01 | 6.0K | 1,323,919 | I | ↗ |
| 2024-10-30 | SALAMON STEVEN A J | Director | M-Exempt | A | Tranche B warrants to purchase F-4 Preferred Stock | 500 | 1,000.00 | 500.0K | 0 | I | ↗ |
| 2024-10-30 | Rosalind Advisors, Inc. | Director | H-ExpireLong | A | 8% CONVERTIBLE NOTE | 0 | 0.00 | — | 0 | I | ↗ |
| 2024-10-30 | Aharon Gil | Director | M-Exempt | A | Tranche B warrants to purchase F-4 Preferred Stock | 500 | 1,000.00 | 500.0K | 0 | I | ↗ |
| 2024-10-22 | MICHEL GERARD J | Director / Officer | M-Exempt | D | Tranche B Warrants to Purchase Common Stock | 16,666 | 6.00 | 100.0K | 0 | D | ↗ |
| 2024-05-23 | Sylvester John Richard | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 7.85 | 176.6K | 22,500 | — | ↗ |
| 2024-05-23 | STOLL ROGER G PHD | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 10.16 | 91.4K | 9,000 | — | ↗ |
| 2024-05-23 | SALAMON STEVEN A J | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 7.85 | 176.6K | 22,500 | — | ↗ |
| 2024-05-23 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 7.85 | 176.6K | 22,500 | — | ↗ |
| 2024-05-23 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 7.85 | 176.6K | 22,500 | — | ↗ |
| 2024-05-23 | Aharon Gil | Director | A-Award | A | Stock Option (right to buy) | 22,500 | 7.85 | 176.6K | 22,500 | — | ↗ |
| 2024-04-18 | SALAMON STEVEN A J | Director | C-Conversion | A | Common Shares | 991,615 | 0.00 | — | 2,732,586 | — | ↗ |
| 2024-04-18 | Rosalind Advisors, Inc. | Director | X-InTheMoney | A | Common Shares | 619,946 | 6,199.46 | 3.84B | 2,763,468 | — | ↗ |
| 2024-04-18 | Aharon Gil | Director | X-InTheMoney | A | Common Shares | 619,946 | 6,199.46 | 3.84B | 2,681,271 | — | ↗ |
| 2024-03-19 | Vukovic Vojo | Officer | A-Award | A | Common Stock | 26,882 | 3.72 | 100.0K | 126,882 | — | ↗ |
| 2024-03-19 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 26,882 | 3.72 | 100.0K | 1,121,025 | — | ↗ |
| 2024-03-19 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Pre-funded Warrants | 619,946 | 0.01 | 6.2K | 836,133 | — | ↗ |
| 2024-03-19 | Pennell Sandra | Officer | A-Award | A | Common Stock | 26,881 | 3.72 | 100.0K | 61,052 | — | ↗ |
| 2024-03-19 | Muir Kevin | Officer | A-Award | A | Common Stock | 13,441 | 3.72 | 50.0K | 18,582 | — | ↗ |
| 2024-03-19 | MICHEL GERARD J | Director / Officer | A-Award | A | Common Stock | 40,323 | 3.72 | 150.0K | 302,668 | — | ↗ |
| 2024-03-19 | Hoffman David L. | Officer | A-Award | A | Common Stock | 20,161 | 3.72 | 75.0K | 74,330 | — | ↗ |
| 2024-03-19 | Aharon Gil | Director | P-Purchase | A | Common Shares | 26,882 | 3.72 | 100.0K | 1,069,710 | — | ↗ |
| 2024-03-18 | Rook Martha S. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 4.18 | 522.5K | 125,000 | — | ↗ |
| 2024-02-12 | Vukovic Vojo | Officer | A-Award | A | Stock Option (Right to Buy) | 100,500 | 4.78 | 480.4K | 100,500 | — | ↗ |
| 2024-02-12 | Pennell Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 100,500 | 4.78 | 480.4K | 100,500 | — | ↗ |
| 2024-02-12 | Muir Kevin | Officer | A-Award | A | Stock Option (Right to Buy) | 100,500 | 4.78 | 480.4K | 100,500 | — | ↗ |
| 2024-02-12 | MICHEL GERARD J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 301,500 | 4.78 | 1.44M | 301,500 | — | ↗ |
| 2024-02-12 | Hoffman David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,500 | 4.78 | 480.4K | 100,500 | — | ↗ |
| 2023-12-12 | Vukovic Vojo | Officer | P-Purchase | A | Common Stock | 40,000 | 3.00 | 120.0K | 100,000 | — | ↗ |
| 2023-12-08 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 34,000 | 2.94 | 100.0K | 262,345 | — | ↗ |
| 2023-11-17 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 100,000 | 2.40 | 240.4K | 1,038,828 | — | ↗ |
| 2023-11-17 | Pennell Sandra | Officer | P-Purchase | A | Common Stock | 30,000 | 2.43 | 72.9K | 30,000 | — | ↗ |
| 2023-11-16 | Vukovic Vojo | Officer | P-Purchase | A | Common Stock | 60,000 | 2.48 | 148.8K | 60,000 | — | ↗ |
| 2023-11-16 | Hoffman David L. | Officer | P-Purchase | A | Common Stock | 40,000 | 2.48 | 99.2K | 40,000 | — | ↗ |
| 2023-10-13 | Purpura John | Officer | P-Purchase | A | Common Stock | 14,505 | 3.44 | 49.9K | 41,526 | — | ↗ |
| 2023-08-21 | Sylvester John Richard | Director | P-Purchase | A | Common Stock | 10,550 | 4.80 | 50.6K | 10,550 | — | ↗ |
| 2023-08-21 | Rosalind Advisors, Inc. | Director | X-InTheMoney | A | Tranche A Warrant | 0 | 1,000.00 | — | 0 | — | ↗ |
| 2023-08-18 | MICHEL GERARD J | Director / Officer | X-InTheMoney | A | Common Stock | 31,110 | 4.50 | 140.0K | 228,345 | — | ↗ |
| 2023-06-19 | Vukovic Vojo | Officer | — | D | Stock Option (Right to Buy) | 150,000 | 6.29 | 943.5K | 0 | — | ↗ |
| 2023-06-12 | Sylvester John Richard | Director | A-Award | A | Stock Option (Right to Buy) | 19,682 | 7.25 | 142.7K | 19,682 | — | ↗ |
| 2023-06-12 | STOLL ROGER G PHD | Director | A-Award | A | Stock Option (Right to Buy) | 19,682 | 7.25 | 142.7K | 19,682 | — | ↗ |
| 2023-06-12 | SALAMON STEVEN A J | Director | A-Award | A | Stock Option (Right to Buy) | 19,682 | 7.25 | 142.7K | 19,682 | — | ↗ |
| 2023-06-12 | Purpura John | Officer | A-Award | A | Stock Option (Right to Buy) | 59,813 | 7.25 | 433.6K | 59,813 | — | ↗ |
| 2023-06-12 | Pennell Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 7.25 | 725.0K | 100,000 | — | ↗ |
| 2023-06-12 | Muir Kevin | Officer | A-Award | A | Stock Option (Right to Buy) | 59,813 | 7.25 | 433.6K | 59,813 | — | ↗ |
| 2023-06-12 | MICHEL GERARD J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 168,887 | 7.25 | 1.22M | 168,887 | — | ↗ |
| 2023-06-12 | John Johnny | Officer | A-Award | A | Stock Option (Right to Buy) | 59,813 | 7.25 | 433.6K | 59,813 | — | ↗ |
| 2023-06-12 | Hoffman David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 59,813 | 7.25 | 433.6K | 59,813 | — | ↗ |
| 2023-06-12 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Option (Right to Buy) | 19,682 | 7.25 | 142.7K | 19,682 | — | ↗ |
| 2023-06-12 | Aharon Gil | Director | A-Award | A | Stock Option (Right to Buy) | 19,682 | 7.25 | 142.7K | 19,682 | — | ↗ |
| 2023-06-01 | Pennell Sandra | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-18 | Rosalind Advisors, Inc. | Director | H-ExpireLong | A | Pre-Funded Warrant | 538,828 | 0.01 | 5.4K | 719,965 | — | ↗ |
| 2023-03-29 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 19,646 | 4.84 | 95.1K | 197,235 | — | ↗ |
| 2023-02-08 | Purpura John | Officer | A-Award | A | Stock Option (Right to Buy) | 56,160 | 4.67 | 262.3K | 56,160 | — | ↗ |
| 2023-02-08 | Muir Kevin | Officer | A-Award | A | Stock Option (Right to Buy) | 46,800 | 4.67 | 218.6K | 46,800 | — | ↗ |
| 2023-02-08 | MICHEL GERARD J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 140,400 | 4.67 | 655.7K | 140,400 | — | ↗ |
| 2023-02-08 | John Johnny | Officer | A-Award | A | Stock Option (Right to Buy) | 46,800 | 4.67 | 218.6K | 46,800 | — | ↗ |
| 2023-02-08 | Hoffman David L. | Officer | A-Award | A | Stock Option (Right to Buy) | 46,800 | 4.67 | 218.6K | 46,800 | — | ↗ |
| 2023-02-08 | Dias Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 31,200 | 4.67 | 145.7K | 31,200 | — | ↗ |
| 2022-12-14 | SALAMON STEVEN A J | Director | P-Purchase | A | COMMON SHARES | 15,215 | 3.62 | 55.0K | 455,315 | — | ↗ |
| 2022-12-14 | Rosalind Advisors, Inc. | Director | P-Purchase | A | COMMON SHARES | 15,215 | 3.62 | 55.0K | 459,315 | — | ↗ |
| 2022-12-13 | SALAMON STEVEN A J | Director | P-Purchase | A | Pre-Funded Warrant | 692,042 | 2.89 | 2.00M | 1,258,793 | — | ↗ |
| 2022-12-13 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Pre-Funded Warrant | 692,042 | 2.89 | 2.00M | 1,258,793 | — | ↗ |
| 2022-12-13 | MICHEL GERARD J | Officer | P-Purchase | A | Common Stock | 51,725 | 2.90 | 150.0K | 177,589 | — | ↗ |
| 2022-12-13 | Aharon Gil | Director | P-Purchase | A | Pre-Funded Warrant | 692,042 | 2.89 | 2.00M | 1,258,793 | — | ↗ |
| 2022-07-20 | MICHEL GERARD J | Officer | P-Purchase | A | Common Stock | 62,814 | 3.98 | 250.0K | 125,864 | — | ↗ |
| 2022-07-18 | SALAMON STEVEN A J | Director | P-Purchase | A | Pre-Funded Warrant | 566,751 | 0.01 | 5.7K | 566,751 | — | ↗ |
| 2022-07-18 | Aharon Gil | Director | P-Purchase | A | Pre-Funded Warrant | 566,751 | 0.01 | 5.7K | 566,751 | — | ↗ |
| 2022-05-16 | Purpura John | Officer | P-Purchase | A | Common Stock | 3,300 | 4.61 | 15.2K | 27,021 | — | ↗ |
| 2022-05-13 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 5,000 | 5.03 | 25.1K | 440,100 | — | ↗ |
| 2022-05-12 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 6,000 | 4.90 | 29.4K | 29,424 | — | ↗ |
| 2022-05-04 | Sylvester John Richard | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-05-04 | STOLL ROGER G PHD | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-05-04 | SALAMON STEVEN A J | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 6.24 | 56.2K | 9,000 | — | ↗ |
| 2022-05-04 | Muir Kevin | Officer | — | D | Stock Option (Right to Buy) | 30,000 | 15.32 | 459.6K | 0 | — | ↗ |
| 2022-05-04 | Hoffman David L. | Officer | — | D | Stock Option (Right to Buy) | 50,000 | 6.61 | 330.5K | 0 | — | ↗ |
| 2022-05-04 | Dias Anthony | Officer | — | D | Stock Option (Right to Buy) | 30,000 | 7.25 | 217.5K | 0 | — | ↗ |
| 2022-05-04 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Options | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-05-04 | Aharon Gil | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-04-19 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 1,600 | 6.25 | 10.0K | 429,100 | — | ↗ |
| 2022-04-19 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 1,600 | 6.25 | 10.0K | 433,100 | — | ↗ |
| 2022-04-18 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 2,000 | 6.35 | 12.7K | 431,500 | — | ↗ |
| 2022-04-18 | MICHEL GERARD J | Officer | P-Purchase | A | Common Stock | 200 | 6.34 | 1.3K | 61,250 | — | ↗ |
| 2022-04-18 | Aharon Gil | Director | P-Purchase | A | Common Shares | 2,000 | 6.35 | 12.7K | 404,000 | — | ↗ |
| 2022-04-13 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 1,500 | 6.45 | 9.7K | 427,500 | — | ↗ |
| 2022-04-13 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 1,500 | 6.45 | 9.7K | 429,500 | — | ↗ |
| 2022-04-12 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 2,500 | 6.48 | 16.2K | 425,000 | — | ↗ |
| 2022-04-12 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 2,500 | 6.48 | 16.2K | 428,000 | — | ↗ |
| 2022-04-11 | Purpura John | Officer | P-Purchase | A | Common Stock | 5,000 | 6.59 | 33.0K | 23,721 | — | ↗ |
| 2022-04-08 | MICHEL GERARD J | Officer | P-Purchase | A | Common Stock | 1,000 | 6.55 | 6.5K | 61,050 | — | ↗ |
| 2022-04-07 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 1,000 | 6.41 | 6.4K | 423,500 | — | ↗ |
| 2022-04-07 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 1,000 | 6.41 | 6.4K | 425,500 | — | ↗ |
| 2022-04-06 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 1,000 | 6.49 | 6.5K | 422,500 | — | ↗ |
| 2022-04-06 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 1,000 | 6.49 | 6.5K | 424,500 | — | ↗ |
| 2022-04-04 | John Johnny | Officer | — | D | Stock Option (right to buy) | 50,000 | 10.16 | 508.0K | 0 | — | ↗ |
| 2022-02-08 | Purpura John | Officer | A-Award | A | Employee Stock Option (right to buy) | 46,198 | 7.14 | 329.9K | 46,198 | — | ↗ |
| 2022-02-08 | MICHEL GERARD J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 116,137 | 7.14 | 829.2K | 116,137 | — | ↗ |
| 2021-12-30 | SALAMON STEVEN A J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-30 | Rosalind Advisors, Inc. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-30 | Aharon Gil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-02 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 23,200 | 8.61 | 199.8K | 59,050 | — | ↗ |
| 2021-09-01 | Padula Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 9.85 | 295.5K | 30,000 | — | ↗ |
| 2021-08-05 | Sylvester John Richard | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 10.16 | 91.4K | 9,000 | — | ↗ |
| 2021-08-05 | STOLL ROGER G PHD | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 10.16 | 91.4K | 9,000 | — | ↗ |
| 2021-08-05 | SALAMON STEVEN A J | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 10.16 | 91.4K | 9,000 | — | ↗ |
| 2021-08-05 | Purpura John | Officer | A-Award | A | Employee Stock Option (right to buy) | 45,000 | 10.16 | 457.2K | 45,000 | — | ↗ |
| 2021-08-05 | MICHEL GERARD J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 10.16 | 1.27M | 125,000 | — | ↗ |
| 2021-08-05 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 10.16 | 91.4K | 9,000 | — | ↗ |
| 2021-08-05 | Aharon Gil | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 10.16 | 91.4K | 9,000 | — | ↗ |
| 2021-06-30 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 5,500 | 12.76 | 70.2K | 419,500 | — | ↗ |
| 2021-06-30 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 5,500 | 12.76 | 70.2K | 421,500 | — | ↗ |
| 2021-06-28 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 5,000 | 11.56 | 57.8K | 414,000 | — | ↗ |
| 2021-06-28 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 5,000 | 11.56 | 57.8K | 416,000 | — | ↗ |
| 2021-06-28 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 6,250 | 11.93 | 74.6K | 35,850 | — | ↗ |
| 2021-06-25 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 6,600 | 11.35 | 74.9K | 29,600 | — | ↗ |
| 2021-06-24 | SALAMON STEVEN A J | Director | C-Conversion | D | Series E-1 Convertible Preferred Stock | 1,122 | 0.00 | — | 1,137 | — | ↗ |
| 2021-06-24 | Rosalind Advisors, Inc. | Director | C-Conversion | D | Series E-1 Convertible Preferred Stock | 1,122 | 0.00 | — | 1,137 | — | ↗ |
| 2021-06-24 | Aharon Gil | Director | C-Conversion | D | Series E-1 Convertible Preferred Stock | 1,122 | 0.00 | — | 1,137 | — | ↗ |
| 2021-06-23 | SALAMON STEVEN A J | Director | C-Conversion | D | Series E Convertible Preferred Stock | 7,561 | 0.00 | — | 2,749 | — | ↗ |
| 2021-06-23 | Rosalind Advisors, Inc. | Director | C-Conversion | D | Series E Convertible Preferred Stock | 7,561 | 0.00 | — | 2,749 | — | ↗ |
| 2021-06-23 | Aharon Gil | Director | C-Conversion | A | Common Shares | 877,379 | 0.00 | — | 402,000 | — | ↗ |
| 2021-05-13 | Purpura John | Officer | P-Purchase | A | Common Stock | 4,000 | 9.42 | 37.7K | 18,713 | — | ↗ |
| 2021-04-05 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 15,500 | 12.88 | 199.6K | 23,000 | — | ↗ |
| 2021-03-31 | SALAMON STEVEN A J | Director | F-InKind | A | Common Shares | 215,000 | 10.00 | 2.15M | 404,500 | — | ↗ |
| 2021-03-31 | Rosalind Advisors, Inc. | Director | X-InTheMoney | A | Common Shares | 215,000 | 10.00 | 2.15M | 406,500 | — | ↗ |
| 2021-03-31 | Aharon Gil | Director | X-InTheMoney | A | Common Shares | 215,000 | 10.00 | 2.15M | 402,000 | — | ↗ |
| 2020-12-11 | MICHEL GERARD J | Director / Officer | P-Purchase | A | Common Stock | 7,500 | 13.25 | 99.4K | 7,500 | — | ↗ |
| 2020-11-23 | Sylvester John Richard | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 11.67 | 350.1K | 30,000 | — | ↗ |
| 2020-11-23 | STOLL ROGER G PHD | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 11.67 | 466.8K | 40,000 | — | ↗ |
| 2020-11-23 | SALAMON STEVEN A J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 11.67 | 233.4K | 20,000 | — | ↗ |
| 2020-11-23 | Purpura John | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 11.67 | 2.04M | 175,000 | — | ↗ |
| 2020-11-23 | Padula Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 20,000 | 11.67 | 233.4K | 20,000 | — | ↗ |
| 2020-11-23 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 11.67 | 233.4K | 20,000 | — | ↗ |
| 2020-11-23 | Aharon Gil | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 11.67 | 233.4K | 20,000 | — | ↗ |
| 2020-11-19 | Purpura John | Officer | P-Purchase | A | Common Stock | 1,600 | 12.68 | 20.3K | 14,713 | — | ↗ |
| 2020-11-17 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 2,500 | 12.11 | 30.3K | 189,500 | — | ↗ |
| 2020-11-17 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 2,500 | 12.11 | 30.3K | 191,500 | — | ↗ |
| 2020-11-16 | Aharon Gil | Director | P-Purchase | A | Common Shares | 2,000 | 12.00 | 24.0K | 187,000 | — | ↗ |
| 2020-11-13 | SALAMON STEVEN A J | Director | P-Purchase | A | Common Shares | 2,000 | 11.51 | 23.0K | 187,000 | — | ↗ |
| 2020-11-13 | Rosalind Advisors, Inc. | Director | P-Purchase | A | Common Shares | 4,000 | 11.75 | 47.0K | 189,000 | — | ↗ |
| 2020-10-01 | MICHEL GERARD J | Director / Officer | A-Award | A | Employee Stock Option (right to buyer) | 498,000 | 0.00 | — | 498,000 | — | ↗ |
| 2020-06-11 | Padula Christine | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-08 | Taglietti Marco | Director | C-Conversion | A | Common Stock | 6,000 | 1,000.00 | 6.00M | 6,000 | — | ↗ |
| 2020-05-08 | Simpson Jennifer K. | Director / Officer | C-Conversion | A | Common Stock | 14,700 | 1,000.00 | 14.70M | 25,021 | — | ↗ |
| 2020-05-08 | STOLL ROGER G PHD | Director | C-Conversion | A | Common Stock | 9,300 | 1,000.00 | 9.30M | 9,309 | — | ↗ |
| 2020-05-08 | Rueckert William Dodge | Director | C-Conversion | D | Series E Convertible Preferred Stock | 60 | 0.00 | — | 0 | — | ↗ |
| 2020-05-08 | Purpura John | Officer | C-Conversion | A | Common Stock | 6,500 | 1,000.00 | 6.50M | 13,121 | — | ↗ |
| 2020-05-08 | Keck Barbra | Officer | C-Conversion | A | Common Stock | 6,800 | 1,000.00 | 6.80M | 12,851 | — | ↗ |
| 2020-05-06 | Simpson Jennifer K. | Director / Officer | A-Award | A | Common Stock | 10,310 | 0.00 | — | 10,321 | — | ↗ |
| 2020-05-06 | Purpura John | Officer | A-Award | A | Common Stock | 6,613 | 0.00 | — | 6,621 | — | ↗ |
| 2020-05-06 | Keck Barbra | Officer | A-Award | A | Common Stock | 6,040 | 0.00 | — | 6,051 | — | ↗ |
| 2020-05-05 | SALAMON STEVEN A J | Director | — | I | Common Shares | 0 | 0.00 | — | 185,000 | — | ↗ |
| 2020-05-05 | Rosalind Advisors, Inc. | Director | — | I | Common Shares | 0 | 0.00 | — | 185,000 | — | ↗ |
| 2020-05-05 | Aharon Gil | Director | — | I | Series E-1 Convertible Preferred Stock | 2,875 | 10.00 | 28.8K | 0 | — | ↗ |
| 2020-02-14 | CZEREPAK ELIZABETH | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-24 | SALAMON STEVEN A J | Director | — | I | 2019 Warrant | 853,956 | 10.00 | 8.54M | 0 | — | ↗ |
| 2019-12-24 | Rosalind Advisors, Inc. | Director | — | I | 2019 Warrant | 853,956 | 10.00 | 8.54M | 0 | — | ↗ |
| 2019-12-24 | Aharon Gil | Director | — | I | 2019 Warrant | 853,956 | 10.00 | 8.54M | 0 | — | ↗ |
| 2019-07-25 | STOLL ROGER G PHD | Director | P-Purchase | A | Series E Convertible Preferred Stock | 93 | 0.06 | 5.58 | 93 | — | ↗ |
| 2019-07-24 | Sylvester John Richard | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-15 | Taglietti Marco | Director | P-Purchase | A | Common Stock Warrant (Right to Buy) | 1,000,000 | 0.06 | 60.0K | 1,000,000 | — | ↗ |
| 2019-07-15 | Simpson Jennifer K. | Director / Officer | P-Purchase | A | Common Stock Warrant (Right to Buy) | 2,450,000 | 0.06 | 147.0K | 2,450,000 | — | ↗ |
| 2019-07-15 | Rueckert William Dodge | Director | P-Purchase | A | Series E Convertible Preferred Stock | 60 | 0.06 | 3.60 | 60 | — | ↗ |
| 2019-07-15 | Purpura John | Officer | P-Purchase | A | Series E Convertible Preferred Stock | 65 | 0.06 | 3.90 | 65 | — | ↗ |
| 2019-07-15 | Keck Barbra | Officer | P-Purchase | A | Common Stock Warrant (Right to Buy) | 1,113,333 | 0.06 | 66.8K | 1,113,333 | — | ↗ |
| 2019-02-01 | Taglietti Marco | Director | A-Award | A | Stock Options | 100,000 | 0.28 | 28.1K | 100,000 | — | ↗ |
| 2019-02-01 | Simpson Jennifer K. | Director / Officer | A-Award | A | Stock Options | 350,000 | 0.28 | 98.4K | 350,000 | — | ↗ |
| 2019-02-01 | STOLL ROGER G PHD | Director | A-Award | A | Stock Options | 100,000 | 0.28 | 28.1K | 100,000 | — | ↗ |
| 2019-02-01 | Rueckert William Dodge | Director | A-Award | A | Stock Options | 100,000 | 0.28 | 28.1K | 100,000 | — | ↗ |
| 2019-02-01 | Purpura John | Officer | A-Award | A | Stock Options | 250,000 | 0.28 | 70.3K | 250,000 | — | ↗ |
| 2019-02-01 | Pedder Simon | Director | A-Award | A | Stock Options | 100,000 | 0.28 | 28.1K | 100,000 | — | ↗ |
| 2019-02-01 | Keck Barbra | Officer | A-Award | A | Stock Options | 250,000 | 0.28 | 70.3K | 250,000 | — | ↗ |
| 2018-09-28 | Simpson Jennifer K. | Officer | P-Purchase | A | COMMON STOCK | 7,399 | 1.75 | 12.9K | 7,500 | — | ↗ |
Executive team
Top executives
EBIT / Employee
22.5K
Shares Outstanding
34.75M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gerard Michel Chief Executive Officer | 635.7K | — | — | 4.77M | 355.0K | — | 5.77M | 82.82% | ↗ |
| 2 | 2025 | Vojislav Vukovic Chief Medical Officer | 488.0K | — | — | 1.38M | 184.0K | — | 2.06M | 67.31% | ↗ |
| 3 | 2025 | Martha Rook Chief Operating Officer | 460.8K | — | — | 1.38M | 180.0K | — | 2.02M | 68.34% | ↗ |
| 4 | 2024 | Gerard Michel Chief Executive Officer | 560.6K | — | — | 1.23M | 366.8K | — | 2.16M | 57.01% | ↗ |
| 5 | 2024 | Vojislav Vukovic Chief Medical Officer | 465.0K | — | — | 410.0K | 210.6K | — | 1.09M | 37.77% | ↗ |
| 6 | 2024 | Martha Rook Chief Operating Officer | 336.5K | — | — | 445.6K | 151.0K | — | 933.1K | 47.76% | ↗ |
| 7 | 2023 | Gerard Michel Chief Executive Officer | 538.1K | — | — | 1.79M | 189.9K | — | 2.52M | 71.12% | ↗ |
| 8 | 2023 | Gerard Michel, Chief Executive Officer | 538.1K | — | — | 1.79M | 189.9K | — | 2.52M | 71.12% | ↗ |
| 9 | 2023 | John Purpura, M.S. Chief Operating Officer | 409.2K | — | — | 663.8K | 130.0K | — | 1.20M | 55.18% | ↗ |
| 10 | 2023 | Kevin Muir, General Manager, Interventional Oncology | 316.3K | — | — | 621.6K | 78.1K | — | 1.02M | 61.18% | ↗ |
| 11 | 2022 | Gerard Michel, Chief Executive Officer | 521.0K | — | — | 800.5K | 131.2K | 19.5K | 1.47M | 54.37% | ↗ |
| 12 | 2022 | John Purpura, Chief Operating Officer | 396.1K | 89.8K | — | 318.4K | — | — | 804.3K | 39.59% | ↗ |
| 13 | 2022 | John Purpura, M.S. Chief Operating Officer | 396.1K | — | — | 318.4K | 89.8K | — | 804.3K | 39.59% | ↗ |
| 14 | 2022 | Johnny John, M.D. Senior Vice President, Clinical Development and Medical Affairs | 393.0K | 79.1K | — | 265.3K | — | — | 737.5K | 35.98% | ↗ |
| 15 | 2021 | Gerard Michel, Chief Executive Officer | 475.2K | 130.7K | — | 1.23M | — | 78.0K | 1.91M | 64.28% | ↗ |
| 16 | 2021 | John Purpura, Chief Operating Officer | 386.8K | 95.7K | — | 442.9K | — | — | 925.5K | 47.86% | ↗ |
| 17 | 2021 | Johnny John, M.D. Senior Vice President, Clinical Development and Medical Affairs | 325.6K | 58.1K | — | 492.1K | — | — | 875.8K | 56.19% | ↗ |
| 18 | 2021 | Johnny John, M.D., Senior Vice President Clinical Development and Medical Affairs | 325.6K | 58.1K | — | 492.1K | — | — | 875.8K | 56.19% | ↗ |
| 19 | 2020 | Gerard Michel Chief Executive Officer | 112.5K | — | — | 5.63M | — | 19.5K | 5.76M | 97.71% | ↗ |
| 20 | 2020 | Gerard Michel, Chief Executive Officer | 112.5K | — | — | 5.63M | — | 19.5K | 5.76M | 97.71% | ↗ |
| 21 | 2020 | John Purpura, Chief Operating Officer | 347.5K | 57.9K | — | 1.98M | — | 32.0K | 2.42M | 81.92% | ↗ |
| 22 | 2020 | Johnny John, M.D., Senior Vice President Clinical Development and Medical Affairs | 256.6K | 23.7K | — | 849.4K | — | — | 1.13M | 75.18% | ↗ |
| 23 | 2020 | Christine Padula Interim Principal Accounting Officer | 160.8K | 15.0K | — | 226.5K | — | 24.5K | 426.8K | 53.07% | ↗ |
| 24 | 2020 | Jennifer K. Simpson, former President/CEO | 253.3K | — | — | — | — | — | 253.3K | 0.00% | ↗ |
| 25 | 2019 | Jennifer K. Simpson, Ph.D. Former President and Chief Executive Officer | 466.6K | 508.5K | — | 90.7K | — | — | 1.07M | 8.51% | ↗ |
| 26 | 2019 | Jennifer K. Simpson, former President/CEO | 466.6K | 508.5K | — | 90.7K | — | — | 1.07M | 8.51% | ↗ |
| 27 | 2019 | Barbra C. Keck, M.B.A. Former Chief Financial Officer | 324.0K | 311.4K | — | 64.8K | — | — | 700.2K | 9.25% | ↗ |
| 28 | 2019 | John Purpura, Chief Operating Officer | 335.0K | 288.2K | — | 59.4K | — | — | 682.5K | 8.70% | ↗ |
| 29 | 2019 | John Purpura, M.S., Chief Operating Officer | 335.0K | 288.2K | — | 59.4K | — | — | 682.5K | 8.70% | ↗ |
| 30 | 2018 | Jennifer K. Simpson, Ph.D. President and Chief Executive Officer | 466.6K | 75.0K | — | — | — | — | 541.6K | 0.00% | ↗ |
| 31 | 2018 | Jennifer K. Simpson, Ph.D. Former President and Chief Executive Officer | 466.6K | 75.0K | — | — | — | — | 541.6K | 0.00% | ↗ |
| 32 | 2018 | John Purpura, M.S. Executive Vice President, Global Head of Operations | 335.0K | 50.0K | — | — | — | — | 385.0K | 0.00% | ↗ |
| 33 | 2018 | John Purpura, M.S., Chief Operating Officer | 335.0K | 50.0K | — | — | — | — | 385.0K | 0.00% | ↗ |
| 34 | 2018 | Barbra C. Keck, M.B.A. Former Chief Financial Officer | 324.0K | 50.0K | — | — | — | — | 374.0K | 0.00% | ↗ |
| 35 | 2018 | Barbra C. Keck, M.B.A. Chief Financial Officer and Secretary | 324.0K | 50.0K | — | — | — | — | 374.0K | 0.00% | ↗ |
| 36 | 2017 | Jennifer K. Simpson, Ph.D. President and Chief Executive Officer | 453.0K | 147.2K | 7.5K | — | — | — | 607.7K | 1.23% | ↗ |
| 37 | 2017 | John Purpura, M.S. Executive Vice President, Global Head of Operations | 316.2K | 92.5K | 7.1K | — | — | — | 415.8K | 1.72% | ↗ |
| 38 | 2017 | Barbra C. Keck, M.B.A. Chief Financial Officer and Secretary | 293.4K | 68.3K | 4.8K | — | — | — | 366.4K | 1.31% | ↗ |
| 39 | 2012 | Eamonn P. Hobbs President, Chief Executive Officer and Director | 485.0K | — | 133.5K | 407.1K | 128.5K | — | 1.15M | 46.84% | ↗ |
| 40 | 2012 | Krishna Kandarpa, M.D., Ph.D. Executive Vice President, Research and Development, and Chief Medical Officer | 398.2K | — | 41.4K | 124.5K | 83.6K | — | 647.7K | 25.62% | ↗ |
| 41 | 2012 | Graham G. Miao Chief Financial Officer | 330.4K | — | 41.4K | 124.5K | 72.5K | 56.0K | 624.8K | 26.56% | ↗ |
| 42 | 2012 | David A. McDonald Former Executive Vice President, Business Development | 343.1K | — | 41.4K | 124.5K | 60.0K | 7.8K | 576.8K | 28.77% | ↗ |
| 43 | 2012 | Peter J. Graham Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources | 330.2K | — | 41.4K | 124.5K | 74.0K | — | 570.0K | 29.11% | ↗ |
| 44 | 2012 | Agustin V. Gago Former Executive Vice President, Global Sales | 312.2K | — | 41.4K | 124.5K | 62.9K | — | 541.0K | 30.67% | ↗ |
| 45 | 2011 | Eamonn P. Hobbs President, Chief Executive Officer and Director | 468.0K | — | 160.5K | 531.5K | 176.0K | — | 1.34M | 51.80% | ↗ |
| 46 | 2011 | David A. McDonald Former Executive Vice President, Business Development | 333.1K | — | 41.7K | 127.6K | 97.6K | 66.6K | 666.7K | 25.39% | ↗ |
| 47 | 2011 | Peter J. Graham Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources | 313.0K | — | 38.5K | 119.1K | 96.5K | — | 567.1K | 27.79% | ↗ |
| 48 | 2011 | Graham G. Miao Chief Financial Officer | 85.7K | 100.0K | 92.3K | 242.0K | 27.0K | 14.9K | 561.9K | 59.49% | ↗ |
| 49 | 2011 | Agustin V. Gago Former Executive Vice President, Global Sales | 292.1K | — | 38.5K | 119.1K | 87.0K | — | 536.7K | 29.36% | ↗ |
| 50 | 2011 | Krishna Kandarpa, M.D., Ph.D. Executive Vice President, Research and Development, and Chief Medical Officer | 386.6K | — | — | — | 119.7K | — | 506.3K | 0.00% | ↗ |
| 51 | 2010 | Krishna Kandarpa, M.D., Ph.D. Executive Vice President, Research and Development, and Chief Medical Officer | 375.0K | — | — | 342.3K | 53.6K | — | 770.8K | 44.40% | ↗ |
| 52 | 2010 | Eamonn P. Hobbs President, Chief Executive Officer and Director | 435.4K | — | — | 177.8K | 102.7K | — | 715.8K | 24.83% | ↗ |
| 53 | 2010 | Peter J. Graham Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources | 189.2K | — | — | 383.8K | 64.8K | — | 637.9K | 60.18% | ↗ |
| 54 | 2010 | Peter J. Graham Executive Vice President, General Counsel | 189.2K | — | — | 383.8K | 64.8K | — | 637.9K | 60.18% | ↗ |
| 55 | 2010 | David A. McDonald Former Executive Vice President, Business Development | 325.0K | — | — | — | 67.5K | — | 392.5K | 0.00% | ↗ |
| 56 | 2010 | Agustin V. Gago Former Executive Vice President, Global Sales | 285.0K | — | — | — | 39.9K | — | 324.9K | 0.00% | ↗ |
| 57 | 2009 | Jason Rifkin Senior Vice President Clinical Operations and Corporate Secretary David A. McDonald Chief Financial Officer Eamonn P. Hobbs President, CEO and Director Krishna Kandarpa, M.D., Ph.D . Executive Vice President, Research Development, and Chief Medical Officer Barbra Keck , Vice President Controller | 97.3K | 30.0K | 196.0K | 645.2K | — | 125.0K | 1.09M | 76.93% | ↗ |
| 58 | 2008 | Richard Taney President, CEO, Treasurer and Director | 396.0K | 60.0K | 108.1K | 87.9K | — | 75.0K | 727.0K | 26.96% | ↗ |
| 59 | 2008 | Paul Feinstein Former CFO and Treasurer | 145.0K | — | — | — | — | 50.0K | 178.2K | 0.00% | ↗ |
| 60 | 2008 | Jason Rifkin Senior Vice President Clinical Operations and Secretary | 150.0K | — | — | 20.2K | — | — | 170.2K | 11.87% | ↗ |
| 61 | 2007 | Richard Taney President, CEO and Director | 373.0K | — | 211.0K | 225.5K | — | — | 809.5K | 53.92% | ↗ |
| 62 | 2007 | Richard Taney President, CEO, Treasurer and Director | 373.0K | — | 211.0K | 225.5K | — | — | 809.5K | 53.92% | ↗ |
| 63 | 2007 | Seymour Fein, M.D., Chief Medical Officer | 216.0K | — | — | — | — | 31.9K | 247.9K | 0.00% | ↗ |
| 64 | 2007 | Paul Feinstein Former CFO and Treasurer | 135.0K | 20.0K | — | 16.8K | — | — | 171.8K | 9.78% | ↗ |
| 65 | 2007 | Paul Feinstein, CFO and Treasurer | 135.0K | 20.0K | — | 16.8K | — | — | 171.8K | 9.75% | ↗ |
| 66 | 2007 | Jason Rifkin Senior Vice President Clinical Operations and Secretary | 87.5K | — | — | 32.1K | — | — | 119.6K | 26.84% | ↗ |
| 67 | 2007 | Samuel Herschkowitz, M.D., Former Chief Operating Officer | 112.0K | — | — | — | — | — | 112.0K | 0.00% | ↗ |
| 68 | 2006 | Seymour Fein, M.D., Chief Medical Officer | 240.0K | — | — | — | — | 20.3K | 260.3K | 0.00% | ↗ |
| 69 | 2006 | Paul Feinstein Former CFO and Treasurer | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 70 | 2006 | Paul Feinstein, CFO and Treasurer | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 71 | 2006 | Samuel Herschkowitz, M.D., Former Chief Operating Officer | 46.9K | — | — | 52.4K | — | — | 99.3K | 52.78% | ↗ |
| 72 | 2006 | Richard Taney President, CEO, Treasurer and Director | 10.0K | — | — | 52.4K | — | — | 62.4K | 83.97% | ↗ |
| 73 | 2006 | Richard Taney President, CEO and Director | 10.0K | — | — | 52.4K | — | — | 62.4K | 83.97% | ↗ |
| 74 | 2006 | Summary Compensation Table for 2006 Name and Principal Position | 2.0K | 2.0K | 2.0K | — | 2.0K | 2.0K | 2.0K | 100.00% | ↗ |
| 75 | 2006 | Jason Rifkin Senior Vice President Clinical Operations and Secretary | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gerard J. Michel | Chief Executive Officer & Director | 990.7K | male |
| Vojislav Vukovic | Chief Medical Officer | 672.0K | — |
| Martha S. Rook | Chief Operating Officer | 640.8K | — |
| Johnny John | Senior Vice President of Clinical Operations & Medical Affairs | 472.2K | — |
| Kevin Muir | Chief Commercial Officer | 394.4K | male |
| David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | — | male |
| Michael Brunner | Senior Vice President of Interventional Oncology | — | — |
| Sandra Pennell | Chief Financial Officer | — | female |
ESG Rating
ESG Score History MEDICAL - SPECIALTIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DCTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
